Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. Amrane K, et al. Among authors: geier m. Cancer Med. 2020 Apr;9(7):2309-2316. doi: 10.1002/cam4.2806. Epub 2020 Feb 5. Cancer Med. 2020. PMID: 32022459 Free PMC article. Clinical Trial.
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant É, Bizec JL, Bernier C, Quéré G, Amrane K, Gaye E, Lucia F, Burte E, Chouaid C, Robinet G. Geier M, et al. Cancer Med. 2020 Oct;9(19):6923-6932. doi: 10.1002/cam4.3120. Epub 2020 May 15. Cancer Med. 2020. PMID: 32412157 Free PMC article.
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).
Renaud E, Ricordel C, Corre R, Leveiller G, Gadby F, Babey H, Annic J, Lucia F, Bourbonne V, Robinet G, Descourt R, Orione C, Quéré G, Geier M. Renaud E, et al. Among authors: geier m. Transl Lung Cancer Res. 2023 Feb 28;12(2):266-276. doi: 10.21037/tlcr-22-556. Epub 2023 Feb 23. Transl Lung Cancer Res. 2023. PMID: 36895931 Free PMC article.
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body radiation therapy.
Lucia F, Louis T, Cousin F, Bourbonne V, Visvikis D, Mievis C, Jansen N, Duysinx B, Le Pennec R, Nebbache M, Rehn M, Hamya M, Geier M, Salaun PY, Schick U, Hatt M, Coucke P, Hustinx R, Lovinfosse P. Lucia F, et al. Among authors: geier m. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1097-1108. doi: 10.1007/s00259-023-06510-y. Epub 2023 Nov 21. Eur J Nucl Med Mol Imaging. 2024. PMID: 37987783
Identification of CT radiomic features robust to acquisition and segmentation variations for improved prediction of radiotherapy-treated lung cancer patient recurrence.
Louis T, Lucia F, Cousin F, Mievis C, Jansen N, Duysinx B, Le Pennec R, Visvikis D, Nebbache M, Rehn M, Hamya M, Geier M, Salaun PY, Schick U, Hatt M, Coucke P, Lovinfosse P, Hustinx R. Louis T, et al. Among authors: geier m. Sci Rep. 2024 Apr 19;14(1):9028. doi: 10.1038/s41598-024-58551-4. Sci Rep. 2024. PMID: 38641673 Free PMC article.
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I; GFPC Team. Vergnenegre A, et al. Among authors: geier m. Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20. Cancer Med. 2020. PMID: 31747137 Free PMC article.
370 results